CytomX Therapeutics Inc (CTMX) — Cash Flow Quality Index
CytomX Therapeutics Inc (CTMX) has a Cash Flow Quality Index of -0.89x as of March 2025. Operating cash flow of $-21.04 Million is below net income of $23.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CytomX Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
CytomX Therapeutics Inc Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for CytomX Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CTMX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for CytomX Therapeutics Inc (2024–2024)
Year-by-year earnings quality comparison for CytomX Therapeutics Inc. For live market cap and the full company financial profile, see CytomX Therapeutics Inc market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -2.71x | $-86.23 Million | $31.87 Million | — |